These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 33947964)

  • 21. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.
    Li M; Li C; Ke L; Zhan M; Cheng M
    Oncol Lett; 2018 Dec; 16(6):7057-7067. PubMed ID: 30546439
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation.
    Ono A; Kenmotsu H; Watanabe M; Serizawa M; Mori K; Imai H; Taira T; Naito T; Murakami H; Nakajima T; Ohde Y; Endo M; Yamamoto N; Koh Y; Takahashi T
    Ann Oncol; 2014 Oct; 25(10):1948-1953. PubMed ID: 25009007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival of lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Yu CJ; Tsai MF; Liao WY; Yang CH; Jan IS; Yang PC; Shih JY
    Eur Respir J; 2013 Jun; 41(6):1409-18. PubMed ID: 23018906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p14ARF inhibits the growth of p53 deficient cells in a cell-specific manner.
    Li Y; He L; Bruce A; Parihar K; Ingram A; Liu L; Tang D
    Biochim Biophys Acta; 2006 Aug; 1763(8):787-96. PubMed ID: 16764954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.
    Chiu CH; Ho HL; Doong H; Yeh YC; Chen MY; Chou TY; Tsai CM
    Oncotarget; 2015 Apr; 6(10):8407-17. PubMed ID: 25823662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.
    Makino Y; Yoon JH; Bae E; Kato M; Miyazawa K; Ohira T; Ikeda N; Kuroda M; Mamura M
    Biochem Biophys Res Commun; 2017 Mar; 484(2):269-277. PubMed ID: 28115165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level.
    Guo L; Chen Z; Xu C; Zhang X; Yan H; Su J; Yang J; Xie Z; Guo W; Li F; Wu Y; Zhou Q
    BMC Cancer; 2019 Apr; 19(1):369. PubMed ID: 31014278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Yotsukura M; Yasuda H; Shigenobu T; Kaseda K; Masai K; Hayashi Y; Hishida T; Ohtsuka T; Naoki K; Soejima K; Betsuyaku T; Asamura H
    Lung Cancer; 2017 Jul; 109():45-51. PubMed ID: 28577949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
    Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
    Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor mutation-specific immunohistochemical antibodies in lung adenocarcinoma.
    Allo G; Bandarchi B; Yanagawa N; Wang A; Shih W; Xu J; Dalby M; Nitta H; To C; Liu N; Sykes J; Tsao MS
    Histopathology; 2014 May; 64(6):826-39. PubMed ID: 24251405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
    Zhou Q; Yang JJ; Chen ZH; Zhang XC; Yan HH; Xu CR; Su J; Chen HJ; Tu HY; Zhong WZ; Yang XN; Wu YL
    J Hematol Oncol; 2016 Sep; 9(1):86. PubMed ID: 27619632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Promoter methylation status and protein expression of p14ARF gene in squamous cell carcinoma and adenocarcinoma of the lung].
    Tian K; Lin L; Jia Z; Guo X; Zhang L
    Zhongguo Fei Ai Za Zhi; 2006 Feb; 9(1):40-4. PubMed ID: 21144280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    Zhang Y; Ma Y; Li Y; Shen X; Yu Y; Pan Y; Zhang Y; Yu S; Zheng D; Zhao Y; Hu H; Sun Y; Zhang Y; Xiang J; Chen H
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):165-171. PubMed ID: 29026990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities.
    Liu M; He WX; Song N; Yang Y; Zhang P; Jiang GN
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):909-913. PubMed ID: 27032467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR mutation and lobar location of lung adenocarcinoma.
    Tseng CH; Chen KC; Hsu KH; Tseng JS; Ho CC; Hsia TC; Su KY; Wu MF; Chiu KL; Liu CM; Wu TC; Chen HJ; Chen HY; Chang CS; Hsu CP; Hsia JY; Chuang CY; Lin CH; Chen JJW; Chen KY; Liao WY; Shih JY; Yu SL; Yu CJ; Yang PC; Yang TY; Chang GC
    Carcinogenesis; 2016 Feb; 37(2):157-162. PubMed ID: 26645716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component.
    Kishi N; Ito M; Miyata Y; Kanai A; Handa Y; Tsutani Y; Kushitani K; Takeshima Y; Okada M
    Ann Surg Oncol; 2020 Mar; 27(3):945-955. PubMed ID: 31732945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.